- Home
- ZEPP vs OCUP Comparison
ZEPP vs OCUP Comparison
Compare ZEPP & OCUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEPP
- OCUP
- Stock Information
- Founded
- ZEPP 2013
- OCUP 2018
- Country
- ZEPP China
- OCUP United States
- Employees
- ZEPP N/A
- OCUP N/A
- Industry
- ZEPP Computer Manufacturing
- OCUP Biotechnology: Pharmaceutical Preparations
- Sector
- ZEPP Technology
- OCUP Health Care
- Exchange
- ZEPP Nasdaq
- OCUP Nasdaq
- Market Cap
- ZEPP 57.5M
- OCUP 53.1M
- IPO Year
- ZEPP N/A
- OCUP N/A
- Fundamental
- Price
- ZEPP $3.26
- OCUP $1.29
- Analyst Decision
- ZEPP
- OCUP Strong Buy
- Analyst Count
- ZEPP 0
- OCUP 3
- Target Price
- ZEPP N/A
- OCUP $18.67
- AVG Volume (30 Days)
- ZEPP 33.4K
- OCUP 92.7K
- Earning Date
- ZEPP 11-18-2024
- OCUP 11-11-2024
- Dividend Yield
- ZEPP N/A
- OCUP N/A
- EPS Growth
- ZEPP N/A
- OCUP N/A
- EPS
- ZEPP N/A
- OCUP N/A
- Revenue
- ZEPP $237,238,260.00
- OCUP $16,449,000.00
- Revenue This Year
- ZEPP N/A
- OCUP N/A
- Revenue Next Year
- ZEPP $18.83
- OCUP $258.69
- P/E Ratio
- ZEPP N/A
- OCUP N/A
- Revenue Growth
- ZEPP N/A
- OCUP N/A
- 52 Week Low
- ZEPP $2.06
- OCUP $1.15
- 52 Week High
- ZEPP $8.40
- OCUP $3.50
- Technical
- Relative Strength Index (RSI)
- ZEPP 48.14
- OCUP 46.50
- Support Level
- ZEPP $3.66
- OCUP $1.24
- Resistance Level
- ZEPP $4.38
- OCUP $1.34
- Average True Range (ATR)
- ZEPP 0.27
- OCUP 0.07
- MACD
- ZEPP -0.04
- OCUP 0.00
- Stochastic Oscillator
- ZEPP 27.94
- OCUP 20.00
About ZEPP Zepp Health Corporation
Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in two segments: Xiaomi Wearable Products and Self-branded products & others. The product portfolio includes smartwatches and fitness bands. The majority is from Self-branded products & other segments. It generates majority of the revenue from Xiaomi Wearable Products segment.
About OCUP Ocuphire Pharma Inc.
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.